Orphazyme may face class action suit from US investors

A potential lawsuit in the US may be on the cards for Copenhagen-based biotech company Orphazyme, according to the company's H1 report. This is happening after several disappointments for the company over the past half-year, though the CEO and CFO say the suit is unfounded.

CFO Anders Vadsholt | Photo: Orphazyme / PR

Copehagen-based biotech company Orphazyme may be facing legal proceedings in the US, as lawyers are hunting for investors to join a possible class action suit.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs